ITRMF · Iterum Therapeutics plc · Financials
$0.00
At close · Sep 8
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“This condition raises substantial doubt about the Company's ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$446
Shares
44.66M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2021
Net Income
-$24.77M
+35.4%
FY2024
Operating Margin
-275732.43%
-266922.4pp
FY2019
Diluted EPS
-$1.26
+57.4%
FY2024
Operating Cash Flow
-$26.77M
+31.9%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | $0 | $0 | $37K | $869K | $508K | $0 | |
| $4.15M | $10.46M | $39.99M | $17.62M | $10.71M | $21.07M | $90.77M | $68.65M | $25.5M | $10.1M | |
| $10.86M | $7.98M | $7.48M | $12.77M | $13.83M | $11.05M | $11.28M | $8.78M | $4.46M | $3.26M | |
| $1.29M | $254K | $1.72M | $1.72M | $1.71M | — | — | — | — | — | |
| $21.03M | $18.7M | $47.47M | $30.38M | $24.54M | $32.13M | $102.06M | $77.43M | $29.96M | $13.36M | |
| -$20.64M | -$18.7M | -$47.47M | -$30.38M | -$24.54M | -$32.13M | -$102.02M | -$76.56M | -$29.46M | -$13.36M | |
| — | — | — | — | — | — | -275732.43% | -8810.01% | -5798.23% | — | |
| $2.75M | $3.31M | $3.15M | $3.18M | — | — | — | — | — | — | |
| $588K | $789K | $1.72M | $819K | — | — | — | — | — | — | |
| -$6.05M | -$5.84M | $9.71M | -$13.75M | -$66.32M | -$19.14M | -$665K | -$25K | $493K | $8000 | |
| — | — | — | — | — | — | $125K | $423K | — | — | |
| -$26.69M | -$24.53M | -$37.76M | -$44.13M | -$90.86M | -$51.26M | -$102.69M | -$76.58M | -$28.96M | -$13.35M | |
| $276K | $240K | $613K | $301K | $705K | $743K | $444K | $472K | $444K | $113K | |
| -$26.96M | -$24.77M | -$38.37M | -$44.43M | -$91.56M | -$52.01M | -$103.13M | -$77.06M | -$29.41M | -$13.46M | |
| — | — | — | — | — | — | -278729.73% | -8867.2% | -5788.58% | — | |
| -$26.96M | -$24.77M | -$38.37M | -$44.43M | -$91.56M | -$52.01M | -$103.13M | -$77.06M | -$29.41M | -$13.46M | |
| -$26.96M | -$24.78M | -$38.02M | -$44.78M | -$91.56M | -$52.01M | — | — | — | — | |
| USD/shares | -$0.70 | -$1.26 | -$2.96 | -$3.63 | -$8.41 | -$32.49 | — | — | — | — |
| USD/shares | -$0.70 | -$1.26 | -$2.96 | -$3.63 | -$8.41 | -$32.49 | — | — | — | — |
| shares | — | 19.7M | 12.96M | 12.24M | 10.89M | 1.6M | 967.87K | 582.27K | 11.48K | 1577.8667 |
| shares | — | 19.7M | 12.96M | 12.24M | 10.89M | 1.6M | 967.87K | 582.27K | 11.48K | 1577.8667 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 7.62×
EV/EBIT
—
Biotechnology median 21.66×
P/E (TTM)
—
Biotechnology median 17.89×